BMC Cancer (Apr 2022)

Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective study

  • Shigemasa Takamizawa,
  • Tatsunori Shimoi,
  • Masayuki Yoshida,
  • Momoko Tokura,
  • Shu Yazaki,
  • Chiharu Mizoguchi,
  • Ayumi Saito,
  • Shosuke Kita,
  • Kasumi Yamamoto,
  • Yuki Kojima,
  • Hitomi Sumiyoshi-Okuma,
  • Tadaaki Nishikawa,
  • Emi Noguchi,
  • Kazuki Sudo,
  • Kan Yonemori

DOI
https://doi.org/10.1186/s12885-022-09514-3
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Routine measurement of tumor markers is not recommended in daily clinical practice for patients with cancer of unknown primary (CUP). We evaluated the diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with CUP. Methods We retrospectively reviewed the medical records of patients who were diagnosed with CUP between October 2010 and July 2015 at the National Cancer Center Hospital. The tumor markers of the patients were examined, including squamous cell carcinoma antigen, cytokeratin fraction, carcinoembryonic antigen, sialyl Lewis X, neuron-specific enolase, pro-gastrin-releasing peptide, α-fetoprotein, protein induced by vitamin K absence or antagonist II, prostate-specific antigen, soluble interleukin-2 receptor, carbohydrate antigen 19–9, cancer antigen 125, cancer antigen 15–3, NCC-ST-439 (ST439), elastase-1, human chorionic gonadotropin, and sialyl-Tn (STN). Results Among 199 patients with suspected CUP, 90 were diagnosed with confirmed CUP (12 in the favorable subset and 78 in the unfavorable subset). No tumor markers showed 100% sensitivity for unfavorable subsets. ST439 (p = 0.03) and STN (p = 0.049) showed 100% specificity for unfavorable subsets. Conclusions For patients with suspected CUP who show elevated ST439 or STN levels, the treatment strategy should be based on the premise that the patient is likely to be placed in the unfavorable subset.

Keywords